Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1960 1
1963 1
1996 2
1997 1
1998 1
2000 1
2001 2
2003 1
2004 1
2005 3
2006 5
2007 3
2008 3
2009 2
2010 1
2011 2
2012 2
2013 3
2014 5
2015 7
2016 1
2017 3
2018 6
2019 4
2020 4
2022 2
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

63 results

Results by year

Filters applied: . Clear all
Page 1
January/February leadership message.
Flattery M. Flattery M. Heart Lung. 2023 Jan-Feb;57:A1-A2. doi: 10.1016/j.hrtlng.2022.09.020. Epub 2022 Oct 12. Heart Lung. 2023. PMID: 36243584 No abstract available.
"Heart failure at either end of the spectrum".
Flattery M. Flattery M. Heart Lung. 2023 Sep-Oct;61:65. doi: 10.1016/j.hrtlng.2023.05.001. Epub 2023 May 6. Heart Lung. 2023. PMID: 37156060 No abstract available.
Herbal therapies and cardiac side effects.
Flattery M. Flattery M. Prog Cardiovasc Nurs. 2008 Fall;23(4):187-90. doi: 10.1111/j.1751-7117.2008.00014.x. Prog Cardiovasc Nurs. 2008. PMID: 19067984 Review. No abstract available.
Amiodarone: development, clinical indications, and safety.
Cahoon W Jr, Flattery MP, Hess ML. Cahoon W Jr, et al. Among authors: flattery mp. Prog Cardiovasc Nurs. 2007 Summer;22(3):173-6. doi: 10.1111/j.0889-7204.2007.07398.x. Prog Cardiovasc Nurs. 2007. PMID: 17786095 Review. No abstract available.
Report from the 2018 consensus conference on immunomodulating agents in thoracic transplantation: Access, formulations, generics, therapeutic drug monitoring, and special populations.
Cochrane AB, Lyster H, Lindenfeld J, Doligalski C, Baran D, Yost C, Shullo M, Schweiger M, Weill D, Stuckey L, Ivulich S, Scheel J, Peters L, Colvin M, Dawson K, Girgis R, Weeks P, Tse T, Russell S, Flattery M, Jennings D, Kittleson M, Miller T, Khuu T, Claridge T, Uber P, Ford K, Ensor CR, Simpson K, Dipchand A, Page RL 2nd. Cochrane AB, et al. Among authors: flattery m. J Heart Lung Transplant. 2020 Oct;39(10):1050-1069. doi: 10.1016/j.healun.2020.06.024. Epub 2020 Jul 10. J Heart Lung Transplant. 2020. PMID: 32883559
COX-2 inhibitors and cardiovascular risk.
Flattery MP, Hylton Gravatt LA. Flattery MP, et al. Prog Cardiovasc Nurs. 2005 Summer;20(3):123-5. doi: 10.1111/j.0889-7204.2005.04034.x. Prog Cardiovasc Nurs. 2005. PMID: 16030414 Review. No abstract available.
63 results